FibroBiologics Announces 2025 Annual Meeting of Stockholders

3/27/25 8:30:00 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $FBLG alert in real time by email

HOUSTON, March 27, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (NASDAQ:FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that its 2025 Annual Meeting of Stockholders will take place on June 12, 2025, at 11 a.m. CDT, exclusively through a virtual format. The record date for determination of stockholders entitled to vote at the annual meeting is April 14, 2025.

About FibroBiologics

Based in Houston, FibroBiologics is a clinical-stage biotechnology company developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. FibroBiologics holds 160+ US and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer. FibroBiologics represents the next generation of medical advancement in cell therapy. For more information, visit www.FibroBiologics.com.

General Inquiries:

[email protected]

Investor Relations:

Nic Johnson

Russo Partners

(212) 845-4242

[email protected]

Media Contact:

Liz Phillips

Russo Partners

(347) 956-7697

[email protected]

Get the next $FBLG alert in real time by email

Date	Price Target	Rating	Analyst
12/12/2024	$12.00	Buy	Rodman & Renshaw
10/30/2024	$12.00	Buy	H.C. Wainwright
9/24/2024	$12.00	Buy	Maxim Group

FibroBiologics Announces 2025 Annual Meeting of Stockholders

Chat with this insight

Recent Analyst Ratings for
$FBLG

$FBLG
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

SEC Form 4 filed by CHIEF SCIENTIFIC OFFICER Khoja Hamid

SEC Form 4 filed by General Counsel Garcia Ruben A

SEC Form 4 filed by CHIEF EXECUTIVE OFFICER O'Heeron Pete

$FBLG
Leadership Updates

Live Leadership Updates

FibroBiologics Set to Join Russell 2000® Index

FibroBiologics Appoints Ruben A. Garcia as General Counsel

$FBLG
SEC Filings

SEC Form 10-Q filed by FibroBiologics Inc.

FibroBiologics Inc. filed SEC Form 8-K: Leadership Update

SEC Form DEFA14A filed by FibroBiologics Inc.

$FBLG
Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Chief Executive Officer O'Heeron Pete bought $16,269 worth of shares (8,500 units at $1.91), increasing direct ownership by 0.14% to 6,056,647 units (SEC Form 4)

Chief Scientific Officer Khoja Hamid bought $19,000 worth of shares (10,000 units at $1.90), increasing direct ownership by 800% to 11,250 units (SEC Form 4)

$FBLG
Press Releases

Fastest customizable press release news feed in the world

FibroBiologics Presents at the Society for Investigative Dermatology Annual Meeting

FibroBiologics Reports First Quarter 2025 Financial Results and Provides Corporate Update

FibroBiologics Presenting at the ThymUS 2025 Meeting

$FBLG
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Rodman & Renshaw initiated coverage on FibroBiologics with a new price target

H.C. Wainwright initiated coverage on FibroBiologics with a new price target

Maxim Group initiated coverage on FibroBiologics with a new price target

FibroBiologics Announces 2025 Annual Meeting of Stockholders

Chat with this insight

Recent Analyst Ratings for $FBLG

$FBLG Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

SEC Form 4 filed by CHIEF SCIENTIFIC OFFICER Khoja Hamid

SEC Form 4 filed by General Counsel Garcia Ruben A

SEC Form 4 filed by CHIEF EXECUTIVE OFFICER O'Heeron Pete

$FBLG Leadership Updates

Live Leadership Updates

FibroBiologics Set to Join Russell 2000® Index

FibroBiologics Appoints Ruben A. Garcia as General Counsel

$FBLG SEC Filings

SEC Form 10-Q filed by FibroBiologics Inc.

FibroBiologics Inc. filed SEC Form 8-K: Leadership Update

SEC Form DEFA14A filed by FibroBiologics Inc.

$FBLG Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Chief Executive Officer O'Heeron Pete bought $16,269 worth of shares (8,500 units at $1.91), increasing direct ownership by 0.14% to 6,056,647 units (SEC Form 4)

Chief Scientific Officer Khoja Hamid bought $19,000 worth of shares (10,000 units at $1.90), increasing direct ownership by 800% to 11,250 units (SEC Form 4)

$FBLG Press Releases

Fastest customizable press release news feed in the world

FibroBiologics Presents at the Society for Investigative Dermatology Annual Meeting

FibroBiologics Reports First Quarter 2025 Financial Results and Provides Corporate Update

FibroBiologics Presenting at the ThymUS 2025 Meeting

$FBLG Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Rodman & Renshaw initiated coverage on FibroBiologics with a new price target

H.C. Wainwright initiated coverage on FibroBiologics with a new price target

Maxim Group initiated coverage on FibroBiologics with a new price target

Recent Analyst Ratings for
$FBLG

$FBLG
Insider Trading

$FBLG
Leadership Updates

$FBLG
SEC Filings

$FBLG
Insider Purchases

$FBLG
Press Releases

$FBLG
Analyst Ratings